Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community Binding affinity of pyrilutamide!

      in Update  169 upvotes 3 years ago
      Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

      community Thinking about using PP405 and RU58841

      in Research/Science  1 upvotes 3 months ago
      The conversation is about a person using dutasteride and minoxidil for hair loss, considering adding RU58841 and PP405 for more density. They are seeking advice on using these treatments and exploring other options like GT20029.

      community What happened to Breezula ????

      in Research/Science  11 upvotes 3 years ago
      The conversation discusses the effectiveness of a hair loss treatment called CB (Breezula) in comparison to Pyrilutamide, and its potential when combined with Finasteride. There is uncertainty about when or if phase 3 trials for Breezula will begin.

      community Dry and itchy scalp after ru58841 and keto. Advice needed

      in Product  3 upvotes 4 years ago
      The user experienced severe scalp itching after using RU58841 and ketoconazole shampoo, despite trying moisturizing treatments. They suspect the issue is related to the propylene glycol in the vehicle and are seeking alternatives.

      community Update on the ol' crown (oral min/fin)

      in Progress Pictures  1013 upvotes 1 year ago
      Using 2.5mg oral minoxidil and 1mg oral finasteride daily leads to significant hair regrowth without side effects, especially at the crown. Consistency is crucial, and some users consider additional methods like derma rolling.

      community Hope Medicine HMI-115 got 28M$ investment

      in Research/Science  59 upvotes 2 years ago
      Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.